A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Nilotinib (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker
- 17 Feb 2018 Planned End Date changed from 1 Mar 2019 to 1 Dec 2019.
- 17 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.
- 17 Jan 2017 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.